Medpace grew revenue 26% and the stock fell. Here is why.

Medpace had, by one measure, the best quarter in the CRO group. Revenue in Q1 2026 grew more than 26 percent year over year to $706.6 million, and earnings beat expectations. The stock fell anyway. Understanding why is the single clearest lesson in reading a CRO, and it matters to anyone whose job depends on one.

The number that mattered

The market did not care about the 26 percent. It cared about a different number: net book-to-bill of 0.88. Medpace booked $618 million of net new business against the revenue it delivered, and 0.88 means it burned through backlog faster than it replaced it. Management attributed the miss to a combination of elevated backlog cancellations and weak gross bookings in the quarter. Analysts had expected something closer to 1.15, so 0.88 was not just below the healthy line, it was a miss against expectations.

Why the past quarter did not save it

Here is the mechanic that trips people up. Revenue you recognize this quarter was booked one to two years ago. It reflects decisions made in a better environment. Book-to-bill reflects decisions being made now. So a company can show wonderful current revenue, because its old backlog is converting, while its new bookings quietly signal a harder future. That is exactly what a 26 percent revenue print alongside a 0.88 book describes: a strong present built on the past, and a warning about what comes next.

For the roughly 6,300 people who work at Medpace, the 0.88 is the number to sit with, not the 26 percent. A sub-1.0 book, if it persists, means the backlog that funds their work is shrinking. One quarter is not a trend, and Medpace books lumpy, short contracts that swing its ratio around, so a single print could reverse. But it is the kind of signal that, sustained, precedes slower hiring.

What it does and does not mean for workers

It does not mean layoffs are announced or imminent. Medpace is profitable, growing revenue fast, and carrying a backlog near $2.9 billion. What a 0.88 book means is that the forward indicator turned down, and forward indicators are worth watching precisely because they move first. If you work there, this is a quarter to read the next one closely, keep your network warm, and know your market value, not a quarter to panic.

It also illustrates why this metric belongs in every CRO worker's toolkit. Nobody at Medpace needed insider access to see the warning. It was in the public earnings release, in a single ratio, available to anyone who knew to read it.

What the filing cannot tell you

The 0.88 is a forecast about demand. It cannot tell you whether Medpace will respond by trimming staff, freezing hiring, or riding it out on its backlog, or how it treats people when it does adjust. Those outcomes live with the people who work there. If you are at Medpace and watching this, your read on what the company is actually doing is worth more to your peers than any analyst note. Post what you can, and add your datapoint.